Functional modulation of regulatory T cells by IL-2

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Moon, Byung In ^a   Kim, Tae Hun ^a   Seoh, Ju Young ^a  

^a Ewha Womans University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE;

ANIMAL CELL; ANTIGEN PRESENTING CELL; ARTICLE; AUTOCRINE EFFECT; CD4+ CD25+ T LYMPHOCYTE; CD4+ FOXP3+ T LYMPHOCYTE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FLOW CYTOMETRY; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; REGULATORY T LYMPHOCYTE; SPLEEN CELL; ANIMAL; CYTOLOGY; GENE TARGETING; GENETICS; IMMUNOLOGY; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, CD4; FORKHEAD TRANSCRIPTION FACTORS; GENE KNOCK-IN TECHNIQUES; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MICE; MICE, TRANSGENIC; T-LYMPHOCYTES, REGULATORY;

EID: 84951864759     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0141864     Document Type: Article

References (57)

1. Piccirillo CA, Shevach EM. Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin Immunol. 2004; 16: 81-88. PMID: 15036231
2. Piccirillo CA, Shevach EM. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol. 2001; 167: 1137-1140. PMID: 11466326
3. Lim HW, Hillsamer P, Banham AH, Kim CH. Cutting edge: direct suppression of B cells by CD4+ CD25+ regulatory T cells. J Immunol. 2005; 175: 4180-4183. PMID: 16177055
4. Ralainirina N, Poli A, Michel T, Poos L, Andres E, Hentges F, et al. Control of NK cell functions by CD4+ CD25+ regulatory T cells. J Leukoc Biol. 2007; 81: 144-153. PMID: 16959895
5. Piccirillo CA. Regulatory T cells in health and disease. Cytokine. 2008; 43: 395-401. doi: 10.1016/j.cyto.2008.07.469 PMID: 18722786
6. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol. 2004; 22: 531-562. PMID: 15032588
7. Almeida AR, Amado IF, Reynolds J, Berges J, Lythe G, Molina-Paris C, et al. Quorum-Sensing in CD4 (+) T Cell Homeostasis: A Hypothesis and a Model. Front Immunol. 2012; 3: 125. doi: 10.3389/fimmu.2012.00125 PMID: 22654881
8. Hofer T, Krichevsky O, Altan-Bonnet G. Competition for IL-2 between Regulatory and Effector T Cells to Chisel Immune Responses. Front Immunol. 2012; 3: 268. doi: 10.3389/fimmu.2012.00268 PMID: 22973270
9. Klatzmann D, Abbas AK. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol. 2015; 15: 283-294. doi: 10.1038/nri3823 PMID: 25882245
10. Setoguchi R, Hori S, Takahashi T, Sakaguchi S. Homeostatic maintenance of natural Foxp3(+) CD25 (+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med. 2005; 201: 723-735. PMID: 15753206
11. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006; 441: 235-238. PMID: 16648838
12. Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol. 2004; 4: 665-674. PMID: 15343366
13. Malek TR, Yu A, Vincek V, Scibelli P, Kong L. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. Immunity. 2002; 17: 167-178. PMID: 12196288
14. Levings MK, Sangregorio R, Roncarolo MG. Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med. 2001; 193: 1295-1302. PMID: 11390436
15. Thornton AM, Shevach EM. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol. 2000; 164: 183-190. PMID: 10605010
16. Ono M, Yaguchi H, Ohkura N, Kitabayashi I, Nagamura Y, Nomura T, et al. Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature. 2007; 446: 685-689. PMID: 17377532
17. Almeida AR, Zaragoza B, Freitas AA. Indexation as a novel mechanism of lymphocyte homeostasis: the number of CD4+CD25+ regulatory T cells is indexed to the number of IL-2-producing cells. J Immunol. 2006; 177: 192-200. PMID: 16785514
18. de la Rosa M, Rutz S, Dorninger H, Scheffold A. Interleukin-2 is essential for CD4+CD25+ regulatory T cell function. Eur J Immunol. 2004; 34: 2480-2488. PMID: 15307180
19. Jung YJ, Seoh JY. Feedback loop of immune regulation by CD4+CD25+ Treg. Immunobiology. 2009; 214: 291-302. doi: 10.1016/j.imbio.2008.09.004 PMID: 19327546
20. Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med. 1998; 188: 287-296. PMID: 9670041
21. Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol. 2007; 8: 1353-1362. PMID: 17982458
22. Annunziato F, Cosmi L, Liotta F, Lazzeri E, Manetti R, Vanini V, et al. Phenotype, localization, and mechanism of suppression of CD4(+)CD25(+) human thymocytes. J Exp Med. 2002; 196: 379-387. PMID: 12163566
23. Jilaveanu LB, Aziz SA, Kluger HM. Chemotherapy and biologic therapies for melanoma: do they work? Clin Dermatol. 2009; 27: 614-625. doi: 10.1016/j.clindermatol.2008.09.020 PMID: 19880049
24. Margolin KA. Interleukin-2 in the treatment of renal cancer. Semin Oncol. 2000; 27: 194-203. PMID: 10768598
25. Kolb H, Zielasek J, Treichel U, Freytag G, Wrann M, Kiesel U. Recombinant interleukin 2 enhances spontaneous insulin-dependent diabetes in BB rats. Eur J Immunol. 1986; 16: 209-212. PMID: 3514237
26. Gutierrez-Ramos JC, Moreno de Alboran I, Martinez C. In vivo administration of interleukin-2 turns on anergic self-reactive T cells and leads to autoimmune disease. Eur J Immunol. 1992; 22: 2867-2872. PMID: 1425912
27. He H, Wisner P, Yang G, Hu HM, Haley D, Miller W, et al. Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model. J Transl Med. 2006; 4: 24. PMID: 16772043
28. Grinberg-Bleyer Y, Baeyens A, You S, Elhage R, Fourcade G, Gregoire S, et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med. 2010; 207: 1871-1878. doi: 10.1084/jem.20100209 PMID: 20679400
29. Rizzo LV, Miller-Rivero NE, Chan CC, Wiggert B, Nussenblatt RB, Caspi RR. Interleukin-2 treatment potentiates induction of oral tolerance in a murine model of autoimmunity. J Clin Invest. 1994; 94: 1668-1672. PMID: 7929845
30. Berntsen A, Brimnes MK, thor Straten P, Svane IM. Increase of circulating CD4+CD25highFoxp3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2. J Immunother. 2010; 33: 425-434. doi: 10.1097/CJI.0b013e3181cd870f PMID: 20386464
31. Wan YY, Flavell RA. Identifying Foxp3-expressing suppressor T cells with a bicistronic reporter. Proc Natl Acad Sci U S A. 2005; 102: 5126-5131. PMID: 15795373
32. Venken K, Thewissen M, Hellings N, Somers V, Hensen K, Rummens JL, et al. A CFSE based assay for measuring CD4+CD25+ regulatory T cell mediated suppression of auto-antigen specific and polyclonal T cell responses. J Immunol Methods. 2007; 322: 1-11. PMID: 17368474
33. Kim HR, Lee A, Choi EJ, Hong MP, Kie JH, Lim W, et al. Reactive oxygen species prevent imiquimod-induced psoriatic dermatitis through enhancing regulatory T cell function. PLoS One. 2014; 9: e91146. doi: 10.1371/journal.pone.0091146 PMID: 24608112
34. Givan AL, Fisher JL, Waugh M, Ernstoff MS, Wallace PK. A flow cytometric method to estimate the precursor frequencies of cells proliferating in response to specific antigens. J Immunol Methods. 1999; 230: 99-112. PMID: 10594357
35. Takahashi T, Kuniyasu Y, Toda M, Sakaguchi N, Itoh M, Iwata M, et al. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol. 1998; 10: 1969-1980. PMID: 9885918
36. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer. 2010; 127: 759-767. doi: 10.1002/ijc.25429 PMID: 20518016
37. Yamazaki S, Iyoda T, Tarbell K, Olson K, Velinzon K, Inaba K, et al. Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med. 2003; 198: 235-247. PMID: 12874257
38. Walker LS, Chodos A, Eggena M, Dooms H, Abbas AK. Antigen-dependent proliferation of CD4+ CD25+ regulatory T cells in vivo. J Exp Med. 2003; 198: 249-258. PMID: 12874258
39. Klein L, Khazaie K, von Boehmer H. In vivo dynamics of antigen-specific regulatory T cells not predicted from behavior in vitro. Proc Natl Acad Sci U S A. 2003; 100: 8886-8891. PMID: 12857946
40. Antony PA, Paulos CM, Ahmadzadeh M, Akpinarli A, Palmer DC, Sato N, et al. Interleukin-2-dependent mechanisms of tolerance and immunity in vivo. J Immunol. 2006; 176: 5255-5266. PMID: 16621991
41. Jang MH, Jung YJ, Kim HR, Moon BI, Seoh JY. Immune Homeostasis Maintained by Tregs. In: Hayashi RS, editor. Regulatory T Cells. New York: Nova Science Publishers, Inc.; 2011. pp. 201-223.
42. Pereira-Santos MC, Baptista AP, Melo A, Alves RR, Soares RS, Pedro E, et al. Expansion of circulating Foxp3+)D25bright CD4+ T cells during specific venom immunotherapy. Clin Exp Allergy. 2008; 38: 291-297. PMID: 18070166
43. Radulovic S, Jacobson MR, Durham SR, Nouri-Aria KT. Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol. 2008; 121: 1467-1472, 1472 e1461. doi: 10.1016/j.jaci.2008.03.013 PMID: 18423565
44. Yu A, Zhu L, Altman NH, Malek TR. A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells. Immunity. 2009; 30: 204-217. doi: 10.1016/j.immuni.2008.11.014 PMID: 19185518
45. Cheng G, Yu A, Malek TR. T-cell tolerance and the multi-functional role of IL-2R signaling in T-regulatory cells. Immunol Rev. 2011; 241: 63-76. doi: 10.1111/j.1600-065X.2011.01004.x PMID: 21488890
46. Sojka DK, Hughson A, Sukiennicki TL, Fowell DJ. Early kinetic window of target T cell susceptibility to CD25+ regulatory T cell activity. J Immunol. 2005; 175: 7274-7280. PMID: 16301632
47. Dooms H, Abbas AK. Revisiting the role of IL-2 in autoimmunity. Eur J Immunol. 2010; 40: 1538-1540. doi: 10.1002/eji.201040617 PMID: 20458706
48. Smith KA. Interleukin-2: inception, impact, and implications. Science. 1988; 240: 1169-1176. PMID: 3131876
49. Suzuki H, Kundig TM, Furlonger C, Wakeham A, Timms E, Matsuyama T, et al. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science. 1995; 268: 1472-1476. PMID: 7770771
50. Lenardo MJ. Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature. 1991; 353: 858-861. PMID: 1944559
51. Waldmann T. The contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for the immunotherapy of rheumatological diseases. Arthritis Res. 2002; 4 Suppl 3: S161-167. PMID: 12110135
52. Oliveira V, Agua-Doce A, Duarte J, Soares MP, Graca L. Regulatory T cell maintenance of dominant tolerance: induction of tissue self-defense? Transpl Immunol. 2006; 17: 7-10. PMID: 17157205
53. Turka LA, Walsh PT. IL-2 signaling and CD4+ CD25+ Foxp3+ regulatory T cells. Front Biosci. 2008; 13: 1440-1446. PMID: 17981641
54. Shaker MA, Younes HM. Interleukin-2: evaluation of routes of administration and current delivery systems in cancer therapy. J Pharm Sci. 2009; 98: 2268-2298. doi: 10.1002/jps.21596 PMID: 19009549
55. Yu A, Snowhite I, Vendrame F, Rosenzwajg M, Klatzmann D, Pugliese A, et al. Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes. Diabetes. 2015; 64: 2172-2183. doi: 10.2337/db14-1322 PMID: 25576057
56. Rosenzwajg M, Churlaud G, Mallone R, Six A, Derian N, Chaara W, et al. Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. J Autoimmun. 2015; 58: 48-58. doi: 10.1016/j.jaut.2015.01.001 PMID: 25634360
57. Webster AC. The CARI guidelines. Calcineurin inhibitors in renal transplantation: the addition of anti-CD25 antibody induction to standard immunosuppressive therapy for kidney transplant recipients. Nephrology (Carlton). 2007; 12 Suppl 1: S75-84.